Roche is striking a $2.3 billion deal with Nurix Therapeutics to develop a blood cancer drug
Nurix receives $700 million upfront to co-develop bexobrutideg, an oral BTK degrader targeting chronic lymphocytic leukemia and other diseases
Overview
Nurix receives $700 million upfront to co-develop bexobrutideg, an oral BTK degrader targeting chronic lymphocytic leukemia and other diseases
Source
Originally published at qz.com.
Related Articles
Disclaimer: This article is for informational purposes only and does not constitute investment advice. Data may be delayed up to 15 minutes. Past performance is not indicative of future results. Consult a licensed financial advisor before making investment decisions.
